NEWYou can now listen to Fox News articles!
A federal judge allowed the abortion pill mifepristone to continue being distributed by mail nationwide for now, but warned the Biden-era policy could soon face major legal changes as a Food and Drug Administration (FDA) safety review of the drug unfolds.
The legal challenge to the U.S. Food and Drug Administration’s January 2023 Risk Evaluation and Mitigation Strategy (REMS) seeks to end the “certified pharmacies” regulation that allows for the drug to be mailed across state lines while the federal agency continues its review.
U.S. District Court Judge David C. Joseph, appointed by President Donald Trump, ruled against Louisiana Attorney General Liz Murrill on Tuesday, citing what he referred to as a “government by lawsuit.”
“…It is the completion of FDA’s promised good faith, evidence-based, and expeditious review of the mifepristone REMS, not “government by lawsuit,” that this Court finds to be in the public interest,” Joseph wrote in his ruling.
PLANNED PARENTHOOD ATTACKS HAWLEY EFFORT TO STRIP FDA APPROVAL OF MIFEPRISTONE
A federal judge Tuesday allowed the abortion pill mifepristone to continue being distributed by mail nationwide. (Evelyn Hockstein/Reuters, File)
Joseph also cited a letter from both Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary asking their respective agencies to “conduct a comprehensive safety review” of the 2023 mifepristone REMS.
Murrill told Fox News Digital she plans on taking Joseph’s ruling to the Fifth Circuit despite the ongoing mifepristone REMS review from both agencies.
“Judge Joseph concluded that Louisiana has standing to sue and is likely to succeed in showing that the 2023 REMS is unlawful,” Murrill said to Fox News Digital in a statement.
YOUNG, GOP SENATORS URGES TRUMP TO REINSTATE ‘PROTECT LIFE RULE’ TO BLOCK TITLE X FUNDS FROM ABORTION CLINICS
Pro-life supporters rally outside the Supreme Court in…
